BD Board Declares Dividend
Get Alerts BDX Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: -13.4%
Join SI Premium – FREE
About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media | Investors |
VP, Public Relations | Shawn Bevec SVP, Investor Relations |
View original content:https://www.prnewswire.com/news-releases/bd-board-declares-dividend-302836855.html
SOURCE BD (Becton, Dickinson and Company)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FF EAI Robotics (FFR) and FF Jointly Launch FF Nova, First Embodied AI Humanoid Robot Priced Below $2,500 in U.S., FF Nova Mini, Physical AI Spark Program Curriculum, Nova Reinforcement Learning Devel
- Building on a Physical AI Technology Foundation, AICT Overcomes Key Challenges in Vehicle–Road Collaboration and Wins First Prize in the Invention and Entrepreneurship Achievement Awards
- CoTec Holdings Corp. Announces Final Closing of Private Placement of Unsecured Convertible Debentures, Total Raise of $20 Million
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share